Martin Stanley Hirsch, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometriosis | 4 | 2022 | 838 | 1.470 |
Why?
|
| Anti-HIV Agents | 25 | 2015 | 4255 | 1.390 |
Why?
|
| HIV-1 | 23 | 2013 | 6939 | 1.060 |
Why?
|
| Clostridium botulinum | 2 | 2014 | 21 | 0.960 |
Why?
|
| Botulism | 2 | 2014 | 21 | 0.950 |
Why?
|
| Drug Resistance, Viral | 13 | 2012 | 820 | 0.930 |
Why?
|
| Reverse Transcriptase Inhibitors | 9 | 2008 | 615 | 0.870 |
Why?
|
| Nandrolone | 1 | 2022 | 17 | 0.860 |
Why?
|
| Botulinum Toxins | 2 | 2014 | 191 | 0.820 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2012 | 113 | 0.790 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2012 | 247 | 0.700 |
Why?
|
| HIV Infections | 29 | 2013 | 16715 | 0.650 |
Why?
|
| Mentors | 1 | 2023 | 631 | 0.640 |
Why?
|
| Cough | 1 | 2021 | 555 | 0.630 |
Why?
|
| Pyrrolidinones | 1 | 2018 | 117 | 0.630 |
Why?
|
| Piracetam | 1 | 2018 | 87 | 0.620 |
Why?
|
| Anti-Retroviral Agents | 8 | 2013 | 1714 | 0.540 |
Why?
|
| Fatigue | 2 | 2021 | 1530 | 0.520 |
Why?
|
| Search Engine | 1 | 2016 | 144 | 0.520 |
Why?
|
| Communicable Diseases | 3 | 2011 | 880 | 0.500 |
Why?
|
| CA-125 Antigen | 1 | 2016 | 286 | 0.490 |
Why?
|
| CD4 Lymphocyte Count | 12 | 2013 | 2560 | 0.470 |
Why?
|
| Consumer Health Information | 1 | 2016 | 211 | 0.470 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2008 | 1870 | 0.470 |
Why?
|
| Antiretroviral Therapy, Highly Active | 8 | 2015 | 1872 | 0.450 |
Why?
|
| Poultry Diseases | 1 | 2012 | 25 | 0.440 |
Why?
|
| Air Microbiology | 1 | 2013 | 87 | 0.420 |
Why?
|
| Orthomyxoviridae | 1 | 2013 | 156 | 0.400 |
Why?
|
| Influenza, Human | 2 | 2013 | 1480 | 0.390 |
Why?
|
| Encephalitis Virus, Eastern Equine | 2 | 2008 | 9 | 0.390 |
Why?
|
| Zoonoses | 1 | 2012 | 183 | 0.380 |
Why?
|
| Inhalation Exposure | 1 | 2013 | 443 | 0.360 |
Why?
|
| HIV Seropositivity | 1 | 2015 | 971 | 0.340 |
Why?
|
| Encephalomyelitis, Eastern Equine | 1 | 2008 | 15 | 0.330 |
Why?
|
| Anticonvulsants | 1 | 2018 | 1910 | 0.320 |
Why?
|
| Pandemics | 3 | 2020 | 8385 | 0.310 |
Why?
|
| HIV Protease Inhibitors | 4 | 2003 | 430 | 0.300 |
Why?
|
| Drug Therapy, Combination | 12 | 2018 | 6487 | 0.300 |
Why?
|
| Human Development | 1 | 2007 | 124 | 0.280 |
Why?
|
| Periodicals as Topic | 2 | 2011 | 1429 | 0.280 |
Why?
|
| Disease Transmission, Infectious | 1 | 2012 | 546 | 0.280 |
Why?
|
| Guanine | 1 | 2007 | 274 | 0.270 |
Why?
|
| Viral Proteins | 1 | 2012 | 1899 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 7270 | 0.250 |
Why?
|
| Internet | 1 | 2016 | 3058 | 0.240 |
Why?
|
| Purine Nucleosides | 1 | 2003 | 30 | 0.240 |
Why?
|
| Dioxolanes | 1 | 2003 | 25 | 0.240 |
Why?
|
| Drug Monitoring | 4 | 2010 | 953 | 0.230 |
Why?
|
| Publishing | 1 | 2011 | 833 | 0.230 |
Why?
|
| Zidovudine | 3 | 2003 | 620 | 0.220 |
Why?
|
| Biomedical Research | 3 | 2015 | 3308 | 0.220 |
Why?
|
| Drug Interactions | 3 | 2019 | 1460 | 0.220 |
Why?
|
| West Nile Fever | 1 | 2003 | 78 | 0.220 |
Why?
|
| West Nile virus | 1 | 2003 | 79 | 0.220 |
Why?
|
| Hepatitis B, Chronic | 1 | 2007 | 392 | 0.220 |
Why?
|
| Meningoencephalitis | 1 | 2003 | 78 | 0.220 |
Why?
|
| Epilepsy | 1 | 2018 | 3284 | 0.220 |
Why?
|
| Cyclic N-Oxides | 1 | 2002 | 78 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3134 | 0.210 |
Why?
|
| Oxazines | 5 | 2006 | 298 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3241 | 0.200 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2003 | 314 | 0.200 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2022 | 113 | 0.200 |
Why?
|
| Humans | 57 | 2024 | 743811 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2013 | 4386 | 0.190 |
Why?
|
| Phloroglucinol | 1 | 2019 | 6 | 0.170 |
Why?
|
| Membrane Proteins | 1 | 2016 | 7880 | 0.170 |
Why?
|
| Antibodies, Viral | 2 | 2008 | 3175 | 0.170 |
Why?
|
| Terpenes | 1 | 2019 | 97 | 0.170 |
Why?
|
| Nelfinavir | 4 | 2005 | 68 | 0.160 |
Why?
|
| Imidazoles | 1 | 2005 | 1206 | 0.160 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 275 | 0.160 |
Why?
|
| Lymphadenitis | 1 | 2019 | 98 | 0.160 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2019 | 419 | 0.160 |
Why?
|
| Developing Countries | 2 | 2007 | 2815 | 0.160 |
Why?
|
| Alanine | 1 | 2020 | 571 | 0.150 |
Why?
|
| Macrophages | 1 | 2012 | 5651 | 0.150 |
Why?
|
| Cross Infection | 1 | 2007 | 1416 | 0.150 |
Why?
|
| Antiviral Agents | 2 | 2007 | 2984 | 0.150 |
Why?
|
| Disease Outbreaks | 1 | 2007 | 1771 | 0.150 |
Why?
|
| Herpesviridae Infections | 1 | 2019 | 277 | 0.150 |
Why?
|
| Drug Tolerance | 1 | 2018 | 376 | 0.140 |
Why?
|
| Female | 28 | 2022 | 380020 | 0.140 |
Why?
|
| Drug Synergism | 3 | 2005 | 1794 | 0.140 |
Why?
|
| HIV | 2 | 2006 | 1604 | 0.140 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2016 | 45 | 0.130 |
Why?
|
| RNA Virus Infections | 1 | 2015 | 17 | 0.130 |
Why?
|
| Poverty | 1 | 2007 | 2660 | 0.130 |
Why?
|
| Plant Extracts | 1 | 2019 | 471 | 0.130 |
Why?
|
| Double-Blind Method | 7 | 2022 | 12020 | 0.130 |
Why?
|
| Pelvic Pain | 1 | 2016 | 274 | 0.120 |
Why?
|
| Treatment Failure | 7 | 2010 | 2617 | 0.120 |
Why?
|
| Confusion | 2 | 2008 | 275 | 0.120 |
Why?
|
| Piperidines | 1 | 2002 | 1601 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2008 | 656 | 0.110 |
Why?
|
| Authorship | 1 | 2016 | 271 | 0.110 |
Why?
|
| Health Personnel | 1 | 2007 | 3217 | 0.110 |
Why?
|
| Piperazines | 3 | 2010 | 2487 | 0.110 |
Why?
|
| Bioterrorism | 1 | 2013 | 143 | 0.110 |
Why?
|
| Fever | 3 | 2019 | 1616 | 0.100 |
Why?
|
| Adult | 25 | 2021 | 213889 | 0.100 |
Why?
|
| Pyrimidines | 3 | 2010 | 2945 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 2715 | 0.100 |
Why?
|
| Comprehension | 1 | 2016 | 610 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2003 | 5096 | 0.100 |
Why?
|
| Infertility, Female | 1 | 2016 | 788 | 0.090 |
Why?
|
| Lamivudine | 4 | 2003 | 342 | 0.090 |
Why?
|
| Pyridines | 1 | 2002 | 2827 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 2012 | 214 | 0.090 |
Why?
|
| Viral Load | 9 | 2010 | 3300 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 10940 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2022 | 8316 | 0.080 |
Why?
|
| Integrase Inhibitors | 1 | 2008 | 12 | 0.080 |
Why?
|
| Tropism | 1 | 2008 | 41 | 0.080 |
Why?
|
| RNA, Viral | 6 | 2010 | 2901 | 0.080 |
Why?
|
| Disease Vectors | 1 | 2008 | 60 | 0.080 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2008 | 65 | 0.080 |
Why?
|
| Drug Resistance, Multiple, Viral | 2 | 2008 | 52 | 0.080 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2008 | 81 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 1596 | 0.080 |
Why?
|
| Male | 20 | 2021 | 349776 | 0.080 |
Why?
|
| Libya | 1 | 2007 | 9 | 0.080 |
Why?
|
| Reverse Transcription | 1 | 2007 | 47 | 0.080 |
Why?
|
| Alkynes | 5 | 2006 | 305 | 0.080 |
Why?
|
| Foreign Professional Personnel | 1 | 2007 | 9 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2019 | 3476 | 0.070 |
Why?
|
| Virus Replication | 2 | 2007 | 2535 | 0.070 |
Why?
|
| Capital Punishment | 1 | 2007 | 31 | 0.070 |
Why?
|
| Cyclopropanes | 5 | 2006 | 415 | 0.070 |
Why?
|
| Jurisprudence | 1 | 2007 | 110 | 0.070 |
Why?
|
| Benzoxazines | 5 | 2006 | 301 | 0.070 |
Why?
|
| Sulfoxides | 1 | 2005 | 48 | 0.060 |
Why?
|
| Molecular Epidemiology | 1 | 2007 | 467 | 0.060 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2004 | 58 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 12954 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 1582 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2008 | 792 | 0.060 |
Why?
|
| Cytomegalovirus | 2 | 2006 | 733 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2012 | 1058 | 0.060 |
Why?
|
| Encephalitis Virus, St. Louis | 1 | 2003 | 1 | 0.060 |
Why?
|
| Indinavir | 1 | 2003 | 74 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2007 | 513 | 0.060 |
Why?
|
| Genes, pol | 1 | 2003 | 51 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2012 | 2683 | 0.060 |
Why?
|
| Immunoglobulin M | 1 | 2008 | 1537 | 0.060 |
Why?
|
| Anniversaries and Special Events | 1 | 2004 | 89 | 0.060 |
Why?
|
| Encephalitis, Viral | 1 | 2003 | 55 | 0.060 |
Why?
|
| Disease Reservoirs | 1 | 2003 | 131 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2003 | 163 | 0.050 |
Why?
|
| Middle Aged | 8 | 2021 | 213241 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2008 | 711 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2005 | 1836 | 0.050 |
Why?
|
| Drug Approval | 1 | 2008 | 742 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2002 | 461 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2004 | 635 | 0.050 |
Why?
|
| Animals | 5 | 2015 | 168660 | 0.050 |
Why?
|
| Glioblastoma | 1 | 2016 | 3480 | 0.050 |
Why?
|
| Oximes | 1 | 2002 | 311 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2008 | 1400 | 0.040 |
Why?
|
| Hepatitis C | 2 | 2007 | 1591 | 0.040 |
Why?
|
| Research Design | 1 | 2015 | 5983 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2007 | 1378 | 0.040 |
Why?
|
| Dextromethorphan | 1 | 2019 | 38 | 0.040 |
Why?
|
| Treatment Outcome | 7 | 2018 | 63042 | 0.040 |
Why?
|
| Aged | 3 | 2021 | 163178 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 820 | 0.040 |
Why?
|
| Hypericum | 1 | 2019 | 58 | 0.040 |
Why?
|
| Groin | 1 | 2019 | 105 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 7908 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2019 | 1654 | 0.040 |
Why?
|
| Pregnancy | 4 | 2008 | 29140 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 2232 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2003 | 1382 | 0.040 |
Why?
|
| Nurses | 1 | 2007 | 2461 | 0.040 |
Why?
|
| Travel | 1 | 2003 | 788 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2016 | 53250 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39001 | 0.040 |
Why?
|
| Diarrhea | 1 | 2003 | 1348 | 0.030 |
Why?
|
| Child | 2 | 2018 | 77637 | 0.030 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 4931 | 0.030 |
Why?
|
| Headache | 1 | 2003 | 1224 | 0.030 |
Why?
|
| Simplexvirus | 1 | 2019 | 803 | 0.030 |
Why?
|
| United States | 3 | 2012 | 69859 | 0.030 |
Why?
|
| Edema | 1 | 2019 | 789 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 8856 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2016 | 528 | 0.030 |
Why?
|
| Viremia | 2 | 2009 | 736 | 0.030 |
Why?
|
| Mutation | 4 | 2008 | 29777 | 0.030 |
Why?
|
| Decision Making | 1 | 2008 | 3887 | 0.030 |
Why?
|
| Stavudine | 2 | 2003 | 85 | 0.030 |
Why?
|
| Didanosine | 2 | 2003 | 153 | 0.030 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 893 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 1104 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 56392 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2004 | 3740 | 0.030 |
Why?
|
| Autoantigens | 1 | 2016 | 892 | 0.020 |
Why?
|
| Patient Selection | 1 | 2003 | 4210 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 85729 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 77410 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 1335 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2005 | 19232 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2016 | 2712 | 0.020 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2008 | 35 | 0.020 |
Why?
|
| Physicians | 1 | 2007 | 4569 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2008 | 99 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 9272 | 0.020 |
Why?
|
| AIDS Serodiagnosis | 1 | 2008 | 184 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1937 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 4183 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6750 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 35409 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 1674 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 2942 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2008 | 2027 | 0.020 |
Why?
|
| Health Services Administration | 1 | 2006 | 64 | 0.020 |
Why?
|
| Ritonavir | 1 | 2007 | 322 | 0.020 |
Why?
|
| Foscarnet | 1 | 2004 | 38 | 0.020 |
Why?
|
| Ganciclovir | 1 | 2004 | 258 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 6237 | 0.010 |
Why?
|
| Genome, Human | 1 | 2016 | 4418 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13273 | 0.010 |
Why?
|
| Brain | 1 | 2008 | 26345 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2005 | 674 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1653 | 0.010 |
Why?
|
| Hepatitis B | 1 | 2006 | 693 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1676 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 2006 | 1347 | 0.010 |
Why?
|
| Acute Disease | 1 | 2009 | 7150 | 0.010 |
Why?
|
| Time Factors | 3 | 2005 | 40038 | 0.010 |
Why?
|
| Biological Evolution | 1 | 2003 | 1079 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 3205 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 999 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 3608 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2006 | 3492 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2006 | 5973 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 5524 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 4326 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 10380 | 0.010 |
Why?
|
| Tuberculosis | 1 | 2006 | 1914 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 4477 | 0.010 |
Why?
|
| Genotype | 1 | 2003 | 12944 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 13980 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2008 | 23327 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 17439 | 0.000 |
Why?
|